Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

Vanucizumab is a novel bispecific antibody inhibiting vascular endothelial growth factor (VEGF-A) and angiopoietin-2 (Ang-2) that demonstrated safety and anti-tumor activity in part I of a phase I study of 42 patients with advanced solid tumors. Part II evaluated the pharmacodynamic effects of vanuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Heil, Florian, Babitzki, Galina, Julien-Laferriere, Alice, Ooi, Chia-Huey, Hidalgo, Manuel, Massard, Christophe, Martinez-Garcia, Maria, Le Tourneau, Christophe, Kockx, Mark, Gerber, Peter, Rossomanno, Simona, Krieter, Oliver, Lahr, Angelika, Wild, Norbert, Harring, Suzana Vega, Lechner, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749407/
https://www.ncbi.nlm.nih.gov/pubmed/33338877
http://dx.doi.org/10.1016/j.tranon.2020.100984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749407/
https://www.ncbi.nlm.nih.gov/pubmed/33338877
http://dx.doi.org/10.1016/j.tranon.2020.100984

Ejemplares similares